Resistance testing: Interpretation and incorporation into HCV treatment algorithms-Reference-Cited by-同舟云学术

Resistance testing: Interpretation and incorporation into HCV treatment algorithms

Published:2017-05 Issue:5 Volume:9 Page:115-120
ISSN:2046-2484
Container-title:Clinical Liver Disease
language:en
Short-container-title:Clinical Liver Disease

Author:

Feld Jordan J.¹^ORCID

Affiliation:

1. Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Sandra Rotman Centre for Global Health; University of Toronto; Toronto ON

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cld.631/fullpdf

Reference11 articles.

1. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens;Pawlotsky;Gastroenterology,2016

2. Post-treatment resistance analysis of hepatitis C virus from phase 2 and 3 clinical trials of ledipasvir/sofosbuvir;Wyles;J Hepatol

3. Oo57: Long-term follow-up of treatment-emergent resistance-associated vairants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens;Krishnan;J Hepatol,2015

4. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir;Krishnan;Antimicrob Agents Chemother,2015

5. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir;Liu;Antimicrob Agents Chemother,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences;Pathogens;2024-08-09

2. Detection of drug resistance mutations of hepatitis C virus in patients with failure of the treatment with direct acting antivirals;Journal of microbiology, epidemiology and immunobiology;2021-03-04

3. Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Pará/Brazil;Virus Research;2021-01

4. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance;Frontiers in Cellular and Infection Microbiology;2020-06-30

5. Hepatitis C genotype 4: A report on resistance‐associated substitutions inNS3,NS5A,andNS5Bgenes;Reviews in Medical Virology;2020-06